NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequenti
The purpose of the study is to evaluate the efficacy and safety of NALIRINOX combined with PD-1 synchronous sequential SBRT or AG combined with PD-1 synchronous sequential SBRT as first line systematical therapy in patients with ocally advanced pancreatic cancer.
| Condition(s) | Locally Advanced Pancreatic Cancer |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The purpose of the study is to evaluate the efficacy and safety of NALIRINOX combined with PD-1 synchronous sequential SBRT or AG combined with PD-1 synchronous sequential SBRT as first line systematical therapy in patients with ocally advanced pancreatic cancer. |
| Who can participate | Inclusion Criteria: 1. Histologically or cytologically confirmed pancreatic cancer; 2. ECOG performance no more than 2; 3. Radiographically assessed as locally advanced pancreatic cancer according to NCCN guidelines; 4. No previous anti-tumor therapy； 5. Able and willing to provide a written informed consent; Exclusion Criteria: * 1\. Prior anti-tumor therapy of any kind; 2. Severe infection (\>NCI CTC grade 2); 3.Patients with autoimmune disease or immune deficiency who are treated with immunosuppressive drugs; 4.Patients with bleeding tendency; 5. Pregnant or lactating women. |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Du Juan |
| Locations | Nanjing, Jiangsu, China; Nanjing, Jiangsu, China |
| Start date | 2024-04-01 |
| NCT ID | NCT06494514 |
| Official listing | https://clinicaltrials.gov/study/NCT06494514 |